Ministry of Health and Long Term Care

Ontario Public Drug Programs
Drug Submission Status

Generic Name: ranibizumab

Brand Name: Lucentis

Strength: 10mg/mL pre-filled syringe

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indication: Neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME), visual impairment due to macular edema secondary to RVO which includes central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO)

Rapid Review: Not Requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Status:
First Review: (Initial Submission)	02/12/2014	11/02/2015	EO decision rendered	Listed on the Ontario Drug Benefit Formulary as a Limited Use Benefit

Rapid Review:

Details of the Rapid Review process can be found at:

Rapid Review Process

Review Status:

- Screening - Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete - Manufacturer did not meet the necessary requirements to allow review to proceed.

Ontario

- Submission complete & under review - Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed - A recommendation was made by the CED.
- Ontario Steering Committee for Cancer Drugs (OSCCD) review completed-A recommendation was made by the OSCCD.
- Executive Officer (EO) decision rendered.

Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

The CED recommendation and the EO decision

Updated: November 27, 2015